Advanced Science and Technology Enterprise Corporation
Takuro Wakabayashi, Managing Partner Jan. 10, 2012 1
About ASTEC
• Seed-focused venture investment company. 2001 Founded by a group of Univ. of Tokyo professors (privately owned) Idea: to fund and support university spinout startups 2002 Formed ATIF (1,040m yen) Specifically targeted to university spinouts 2007 Formed XHGF (1,011m yen) co-managed by JAIC Seed Capital Targeted to general “high-tech” startups
2
Selected Investments
Life Science
Optical
Greentech
3
Life Science Investments
• Oncology-targeted antibody company. • Spinout of University of Tokyo. • Antibodies against over-expressed genes in cancer tissues. • Anti-GPC3 licensed to Chugai (P1) • Acquired by Fuji Film. 4
Life Science Investments
• Cell-cultured vaccine • Partnered with Astellas Pharma • UMN-0501 (ASP7373): pandemic flu (P2) • UMN-0502 (ASP7374): seasonal flu (P2)
5
Life Science Investments
• Kyushu Univ. spinout focused on ophthalmology • ILM Blue (dye for eye surgery) commercialized in Europe under license to DORC (Netherlands)
6
Life Science Investments
• TUAT spinout • Developing SMTP family compounds (plasminogen modulator with nerve protection effect) • Entering into thrombotic stroke prevention P1 clinical trial with 300m yen grant from JST
7
Life Science Investments
• Toray spinout • Developing MCL (Mannose Coated Liposome) as adjuvant for onco-vaccines • Partnered with Toray Engineering to market liposome assembler
8
Take from investor viewpoint • General understanding of “Quality Startup” by capital market is the key to nurture healthy startups in capital intensive segments (i.e. life science).
9